Ann Arbor Stage III Follicular Lymphoma
6 clinical trials · Condition
◉ Watch Ann Arbor Stage III Follicular Lymphoma
| Record | Firm | Date |
|---|---|---|
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma (NCT04450173) | University of California, Davis | 2021-02-24 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956) | Mayo Clinic | 2020-06-15 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (NCT03198026) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-02-20 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma (NCT02532257) | M.D. Anderson Cancer Center | 2016-04-11 |
Track Ann Arbor Stage III Follicular Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.